title: NICE guidance on abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen.
authors.forename: Matthew
authors.initials: M
authors.lastname: Dyer
authors.forename: Fiona
authors.initials: F
authors.lastname: Rinaldi
authors.forename: Elisabeth
authors.initials: E
authors.lastname: George
authors.forename: Amanda I
authors.initials: AI
authors.lastname: Adler
mesh_terms: D000736:Androstenes; D000737:Androstenols / Q000008:administration & dosage; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000191:economics / Q000627:therapeutic use*; D002369:Castration; D003362:Cost-Benefit Analysis; D000077143:Docetaxel; D016527:Drug Costs; D019317:Evidence-Based Medicine; D006801:Humans; D008297:Male; D017410:Practice Guidelines as Topic; D011239:Prednisolone / Q000008:administration & dosage; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000191:economics / Q000401:mortality / Q000556:secondary; D019057:Quality-Adjusted Life Years; D043823:Taxoids / Q000008:administration & dosage; D013727:Terminal Care; D013997:Time Factors; D016896:Treatment Outcome; D006113:United Kingdom
chemical_list: D000736:Androstenes; D000737:Androstenols; D018931:Antineoplastic Agents, Hormonal; D043823:Taxoids; D000077143:Docetaxel; D011239:Prednisolone; C089740:abiraterone